

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 62 (2006) 3435-3438

Efficient highly diastereoselective synthesis of 1,8a-dihydro-7*H*-imidazo[2,1-*b*][1,3]oxazines

Mehdi Adib,^{a,*} Esmaeil Sheibani,^b Manizheh Mostofi,^a Khadijeh Ghanbary^a and Hamid Reza Bijanzadeh^b

^aDepartment of Chemistry, Faculty of Science, University of Tehran, PO Box 14155-6455, Tehran, Iran ^bDepartment of Chemistry, Tarbiat Modarres University, Tehran, Iran

Received 26 May 2005; revised 25 July 2005; accepted 12 January 2006


Available online 20 February 2006

Abstract—1-Alkyl imidazoles react smoothly with dialkyl acetylenedicarboxylates in the presence of pyridine carboxaldehydes to diastereoselectively produce 1,8a-dihydro-7*H*-imidazo[2,1-*b*][1,3]oxazine derivatives in excellent yields. \bigcirc 2006 Elsevier Ltd. All rights reserved.

1. Introduction

The development of simple synthetic routes to widely used organic compounds from readily available reagents is one of the major tasks in organic synthesis.¹ Bridgehead nitrogen heterocycles are of interest because they constitute an important class of natural and nonnatural products, many of which exhibit useful biological activity.² The interest in fused bicyclic 5-6systems with one ring junction nitrogen atom and two extra heteroatoms, one nitrogen in the five-membered ring and one oxygen in the six-membered ring, stems from the appearance of saturated and partially saturated imidazo[2,1-b][1,3]oxazine ring systems in biologically active compounds. Derivatives containing the imidazo[2,1-b][1,3]oxazine ring system have been shown to possess antimicrobial activity. For example, PA-824, PA-822, PA-653, PA-647, PA-601, and PA-602, are all members of bicyclic nitroimidazopyran family, drugs related to nitroimidazoles that have been studied as potent antituberculous compounds against a disease that kills one person every 15 s across the globe. The most promising compound in this PA-824, {4-[((3S)-6-nitro(2H,3H,4H-imidseries. azolo[2,1-b]1,3-oxazaperhydroin-3-yloxy))methyl]phenoxy}trifluoromethane (1) which has a novel mechanism

of action against mycobacterium tuberculosis and *Helobacter pylori* comparable with that of isoniazid.^{3–7} However, only a few synthetic methods have been reported for the preparation of imidazo[2,1-*b*][1,3]oxazine ring systems.^{8–11} As part of our current studies on the development of new routes in heterocyclic synthesis, ^{12–16} we have recently described a simple one-pot synthesis of 5*H*-imidazo[2,1-*b*][1,3]oxazines **2** from the reaction between isocyanides and dialkyl acetylenedicarboxylates in the presence of 4,5-diphenyl-1,3-dihydro-2*H*-imidazol-2-one.¹⁷ In this paper, we wish to report an efficient diastereoselective synthesis of highly functionalized imidazo[2,1-*b*][1,3]oxazines.




2. Results and discussion

The reaction of 1-alkyl imidazoles **3** with dialkyl acetylenedicarboxylates **4** in the presence of pyridine carboxaldehydes **5** in dichloromethane at ambient temperature leads to 1-alkyl-7-pyridin-1,8a-dihydro-7*H*-imidazo[2,1-*b*][1,3]oxazine-5,6-dicarboxylates **6** in 93–97% yields (Scheme 1).

Keywords: Diastereoselective synthesis; Pyridine carboxaldehydes; Acetylenic esters; 1-Alkyl imidazoles; 1,8a-Dihydro-7*H*-imidazo[2,1-*b*][1,3]oxazines.

^{*} Corresponding author. Tel./fax: +98 21 66495291; e-mail: madib@khayam.ut.ac.ir

^{0040–4020/\$ -} see front matter @ 2006 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2006.01.048



Scheme 1.

The reactions were carried out by first mixing the 1-alkyl imidazole **3** and the pyridine carboxaldehyde **5** and then the acetylenic ester **4** was added slowly. The reactions proceeded spontaneously in CH₂Cl₂, and were complete within an hour. The ¹H and ¹³C NMR spectra of the crude product clearly indicated the formation of 1,8a-dihydro-7*H*-imidazo[2,1-*b*][1,3]oxazine derivatives **6**. Any product other than **6** could not be detected by NMR spectroscopy. The reaction is stereoselective and leads to one diastereoisomer. Our attempts to detect the second diastereoisomer in the reaction mixture were not successful.


The structures of compounds **6a–f** were deduced from their elemental analyses, their IR, and high-field ¹H and ¹³C NMR spectra. The mass spectrum of compound **6a** displayed molecular ion (M⁺) peak at m/z=331, which is consistent with the 1:1:1 adduct of 1-methyl imidazole, dimethyl acetylenedicarboxylate, and pyridine-2-carboxaldehyde. The ¹H NMR spectrum of **6a** exhibited five sharp lines readily recognized as arising from N–CH₃ (δ =3.64 ppm), methoxy (δ =3.67 and 3.89 ppm), and methine (δ =5.46 and 6.37 ppm) protons and two fairly broad singlets (δ =6.90 and 7.00 ppm) for NCH=CHN moiety, along with characteristic multiplets for the aromatic protons. The proton decoupled ¹³C NMR spectrum of **6a** showed 16 distinct resonances in agreement with the proposed structure.


The ¹H and ¹³C NMR spectra of compounds **6b–f** are similar to those of **6a** except for the alkyl groups, the ester moieties, and the pyridine rings, which exhibit characteristic signals with appropriate chemical shifts and coupling constants. The signals of the two protons of the NCH=CHN moiety appeared as two doublets (J=1.1 Hz) only for **6d**.

The stereochemistry of the products was established by nuclear Overhauser effect measurement.¹⁸ Thus, when the resonance of C₇H proton of compound **6a** at δ =6.37 ppm was saturated, the intensity of the signal of C_{8a}H proton at δ =5.46 ppm increased by at least 10%. Thus the two protons are in a close *syn* relationship together.

Although we have not established the mechanism of the reaction between 1-alkyl imidazoles and acetylenic esters in the presence of pyridine carboxaldehydes in an experimental manner, a possible explanation is proposed in Scheme 2. The first step may involve addition of the 1-alkyl imidazole to the acetylenic ester and formation of the 1:1 adduct 7. Subsequent nucleophilic attack of the adduct to the aldehyde would yield the 1:1:1 adduct 8. The observed product is formed from the intramolecular addition of the oxygen anion to the imidazolium moiety.

Our attempts to carry out this reaction under the same reaction conditions with a wide range of aliphatic, aromatic, and heteroaromatic aldehydes, from highly electron-rich such as 4-(dimethylamino)benzaldehyde to highly electron-poor such as 4-nitrobenzaldehyde were not successful. For all of the aldehydes apart from 4-nitrobenzaldehyde the TLC and ¹H NMR spectrum of the reaction mixture clearly indicated the formation of 1,8a-dihydroimidazo[1,2-*a*]pyridine-5,6,7,8-tetracarboxy-lates **9** (Scheme 3), and the aldehyde the TLC and ¹H NMR spectrum of the reaction mixture of at least five products together with some of the unreacted 1-alkyl imidazole and the aldehyde.





Scheme 3.

3. Conclusion

In summary, the present method carries the advantage that, not only is the reaction performed under neutral conditions, but also the substances can be mixed without any activation or modification. The simplicity of the present procedure makes it an interesting alternative to other approaches. The procedure described here provides a simple one-pot method for the stereoselective preparation of polyfunctional 1,8a-dihydro-7*H*-imidazo[2,1-*b*][1,3]oxazines.

4. Experimental

Dimethyl- and diethyl acetylenedicarboxylates, 1-methyland 1-butyl imidazoles, and pyridine carbaldehydes were obtained from Merck (Germany) and were used without further purification. Elemental analyses for C, H and N were performed using a Heraeus CHN-O-Rapid analyzer. Mass spectra were recorded on a FINNIGAN-MATT 8430 mass spectrometer operating at an ionization potential of 20 eV. ¹H and ¹³C NMR spectra were measured (CDCl₃ solution) with a Bruker DRX-500 AVANCE spectrometer at 500.1 and 125.8 MHz, respectively. IR spectra were recorded on a Shimadzu IR-460 spectrometer. Chromatography columns were prepared from Merck silica gel 60 mesh.

4.1. General procedure

To a magnetically stirred solution of the appropriate pyridine carbaldehyde (0.107 g, 1 mmol) and the appropriate 1-alkyl imidazole (1 mmol) in dry CH_2Cl_2 (5 mL) was added dropwise a solution of the appropriate dialkyl acetylenedicarboxylate (1 mmol) in CH_2Cl_2 (2 mL) at -5 °C for 10 min. The reaction mixture was then allowed to warm up to room temperature and stirred for 1 h. The solvent was removed and the residue was purified by column chromatography using ethyl acetate as eluent. The solvent was obtained.

4.1.1. Dimethyl 1-methyl-7-pyridin-2-yl-1,8a-dihydro-*7H*-imidazo[2,1-*b*][1,3]oxazine-5,6-dicarboxylate (6a). Viscous brown oil, yield: 0.32 g, 97%. IR (KBr) (v_{max} / cm⁻¹): 1747 and 1720 (C=O), 1631, 1439, 1215, 1148, 761. MS, *m*/*z* (%): 331 (M⁺, 2), 272 (28), 240 (51), 212 (25), 190 (12), 184 (27), 172 (100), 158 (23), 131 (17), 117 (21), 101 (31), 78 (66), 59 (69). Anal. Calcd for C₁₆H₁₇N₃O₅ (331.33): C, 58.00; H, 5.17; N, 12.68. Found: C, 58.2; H, 5.6; N, 11.2%. ¹H NMR (500.1 MHz, CDCl₃): δ 3.64 (3H, s, NCH₃), 3.67 and 3.89 (6H, 2s, 20CH₃), 5.46 (1H, s, N₂CHO), 6.37 (1H, s, Ar-CH), 6.90 and 7.00 (2H, 2s, NCH=CHN), 7.28 (1H, dd, J=6.9, 4.9 Hz, CH), 7.63 (1H, d, J=7.8 Hz, CH), 7.80 (1H, t, J=7.8 Hz, CH), 8.57 (1H, d, J=4.9 Hz, CH). ¹³C NMR (125.8 MHz, CDCl₃): δ 33.28 (NCH₃), 51.60 and 52.99 (2OCH₃), 77.88 (Ar-CH), 96.82 (N₂CHO), 121.96, 123.05, 123.66, 128.22, and 137.30 (5CH), 142.66 (C), 149.34 (CH), 154.96 and 159.49 (2C), 163.54 and 165.90 (2C=O).

4.1.2. Diethyl 1-methyl-7-pyridin-2-yl-1,8a-dihydro-7Himidazo[2,1-b][1,3]oxazine-5,6-dicarboxylate (6b). Viscous brown oil, yield: 0.35 g, 96%. IR (KBr) (v_{max}/cm^{-1} 1): 1740 and 1718 (C=O), 1630, 1375, 1196, 1144, 1043, 910, 733. MS, *m*/*z* (%): 360 (M⁺ +1, 6), 286 (29), 258 (20), 240 (55), 212 (40), 186 (44), 172 (100), 158 (34), 104 (24), 93 (39), 78 (70). Anal. Calcd for $C_{18}H_{21}N_3O_5$ (359.38): C, 60.16; H, 5.89; N, 11.69. Found: C, 59.9; H, 5.8; N, 11.5%. ¹H NMR (500.1 MHz, CDCl₃): δ 1.13 and 1.26 (6H, 2t, J =7.1 Hz, 2OCH₂CH₃), 3.60 (3H, s, NCH₃), 4.01 and 4.26 (4H, 2q, J=7.1 Hz, 2OCH₂CH₃), 5.39 (1H, s, N₂CHO), 6.36 (1H, s, Ar-CH), 6.85 and 6.91 (2H, 2s, NCH=CHN), 7.21 (1H, dd, J = 6.9, 5.3 Hz, CH), 7.56 (1H, d, J = 7.9 Hz, CH), 7.72 (1H, t, J=7.6 Hz, CH), 8.48 (1H, d, J=4.5 Hz, CH). ¹³C NMR (125.8 MHz, CDCl₃): δ 13.68 and 13.96 (2OCH₂CH₃), 33.30 (NCH₃), 60.39 and 62.19 (20CH₂CH₃), 77.45 (Ar-CH), 97.03 (N₂CHO), 121.92, 123.08, 123.62, 127.71, and 137.30 (5CH), 142.65 (C), 149.21 (CH), 154.90 and 159.36 (2C), 163.03 and 165.29 (2C=0).

4.1.3. Dimethyl 1-methyl-7-pyridin-4-yl-1,8a-dihydro-7H-imidazo[2,1-b][1,3]oxazine-5,6-dicarboxylate (6c). Viscous brown oil, yield: 0.32 g, 97%. IR (KBr) $(v_{max}/$ cm⁻¹): 1747 and 1724 (C=O), 1634, 1560, 1443, 1373, 1148, 910, 735. MS, *m/z* (%): 331 (M⁺, 3), 272 (34), 244 (22), 212 (19), 186 (26), 172 (100), 157 (29), 131 (14), 106 (26), 86 (58), 84 (98), 59 (47). Anal. Calcd for C₁₆H₁₇N₃O₅ (331.33): C, 58.00; H, 5.17; N, 12.68. Found: C, 58.0; H, 5.2; N, 12.7%. ¹H NMR (500.1 MHz, CDCl₃): δ 3.31 (3H, s, NCH₃), 3.49 and 3.76 (6H, 2s, 2OCH₃), 5.43 (1H, s, N₂CHO), 6.29 (1H, s, Ar-CH), 6.73 and 6.87 (2H, 2s, NCH=CHN), 7.10 (2H, d, J=5.9 Hz, 2CH), 8.47 (2H, d, J = 5.9 Hz, 2CH). ¹³C NMR (125.8 MHz, CDCl₃): δ 32.15 (NCH₃), 51.32 and 52.75 (2OCH₃), 77.05 (Ar-CH), 95.69 (N₂CHO), 120.44, 121.34, and 128.31 (3CH), 141.59 and 144.78 (2C), 150.05 (CH), 158.75 (C), 163.19 and 165.58 (2C=0).

4.1.4. Dimethyl 1-butyl-7-pyridin-2-yl-1,8a-dihydro-7*H*imidazo[2,1-*b*][1,3]oxazine-5,6-dicarboxylate (6d). Viscous brown oil, yield: 0.35 g, 94%. IR (KBr) (v_{max} /cm⁻¹):

1747 and 1722 (C=O), 1630, 1437, 1373, 1209, 1146, 910, 732. MS, *m/z* (%): 373 (M⁺, 5), 314 (18), 282 (39), 258 (17), 240 (20), 214 (55), 186 (58), 172 (46), 158 (48), 123 (47), 101 (59), 78 (99), 69 (62), 59 (100). Anal. Calcd for C₁₉H₂₃N₃O₅ (373.41): C, 61.12; H, 6.21; N, 11.25. Found: C, 61.2; H, 6.2; N, 11.1%. ¹H NMR (500.1 MHz, CDCl₃): δ 0.86 (3H, t, J=7.0 Hz, CH_2CH_3), 1.24–1.89 (4H, m, $CH_2CH_2CH_3$), 3.58 (3H, s, OCH₃), 3.80 (2H, dt, ²J= 10.1 Hz, ${}^{3}J$ =7.1 Hz, NCH₂), 3.83 (3H, s, OCH₃), 5.41 (1H, s, N₂CHO), 6.32 (1H, s, Ar-CH), 6.91 and 6.98 (2H, 2d, J= 1.1 Hz, NCH=CHN), 7.23 (1H, dd, J=6.8, 5.2 Hz, CH), 7.58 (1H, d, J=7.8 Hz, CH), 7.75 (1H, t, J=7.5 Hz, CH), 8.52 (1H, dd, J=4.9, 1.1 Hz, CH). ¹³C NMR (125.8 MHz, CDCl₃): δ 12.86 (CH₂CH₃), 19.15 and 32.19 (CH₂CH₂-CH₃), 45.72 (NCH₂), 51.08 and 52.46 (2OCH₃), 77.14 (Ar-CH), 96.37 (N₂CHO), 121.16, 121.71, 123.48, 128.33, and 137.30 (5CH), 142.29 (C), 149.23 (CH), 155.22 and 159.67 (2C), 163.47 and 165.96 (2C=O).

4.1.5. Diethyl 1-butyl-7-pyridin-2-yl-1,8a-dihydro-7Himidazo[2,1-b][1,3]oxazine-5,6-dicarboxylate (6e). Viscous brown oil, yield: 0.37 g, 93%. IR (KBr) $(v_{\text{max}}/\text{cm}^{-1})$: 1742 and 1721 (C=O), 1633, 1370, 1189, 1144, 915, 729. MS, *m/z* (%): 401 (M⁺, 3), 330 (61), 303 (32), 284 (89), 256 (30), 231 (45), 217 (100), 201 (43), 188 (82), 174 (61), 160 (66), 135 (50), 124 (44), 119 (68), 106 (36), 96 (54), 80 (98), 58 (93). Anal. Calcd for C₂₁H₂₇N₃O₅ (401.46): C, 62.83; H, 6.78; N, 10.47. Found: C, 62.9; H, 6.9; N, 10.6%. ¹H NMR (500.1 MHz, CDCl₃): δ 0.79 (3H, t, J=7.1 Hz, CH₂CH₂-CH₃), 1.20 and 1.25 (6H, 2t, J=7.3 Hz, 20CH₂CH₃), 1.26-1.91 (4H, m, $CH_2CH_2CH_3$), 3.76 (2H, dt, ${}^2J=10.5$ Hz, ${}^3J=$ 7.4 Hz, NCH₂), 4.05 and 4.29 (4H, 2q, J=7.3 Hz, 2OCH₂CH₃), 5.34 (1H, s, N₂CHO), 6.26 (1H, s, Ar-CH), 6.86 and 6.97 (2H, 2s, NCH=CHN), 7.25 (1H, dd, J=6.8, 5.0 Hz, CH), 7.69 (1H, d, J=7.5 Hz, CH), 7.83 (1H, t, J=7.8 Hz, CH), 8.44 (1H, d, J=4.6 Hz, CH). ¹³C NMR (125.8 MHz, CDCl₃): δ 12.77, 13.01, and 13.30 (3CH₂CH₃), 19.12 and 32.08 (CH₂CH₂CH₃), 45.61 (NCH₂), 59.93 and 61.70 (2OCH₂CH₃), 78.91 (Ar-CH), 96.54 (N₂CHO), 121.06, 121.56, 123.37, 128.31, and 137.16 (5CH), 142.38 (C), 149.11 (CH), 155.32 and 159.71 (2C), 163.04 and 165.38 (2C=O).

4.1.6. Dimethyl 1-butyl-7-pyridin-4-yl-1,8a-dihydro-7*H*imidazo[2,1-*b*][1,3]oxazine-5,6-dicarboxylate (6f). Viscous brown oil, yield: 0.35 g, 95%. IR (KBr) (v_{max}/cm^{-1}): 1747 and 1724 (C=O), 1633, 1599, 1442, 1373, 1209, 1147, 910, 735. MS, *m*/*z* (%): 373 (M⁺, 2), 288 (18), 228 (46), 214 (21), 200 (24), 172 (33), 158 (29), 125 (100), 106 (25), 97 (77), 82 (73), 69 (30), 59 (47). Anal. Calcd for C₁₉H₂₃N₃O₅ (373.41): C, 61.12; H, 6.21; N, 11.25. Found: C, 61.1; H, 6.2; N, 11.4%. ¹H NMR (500.1 MHz, CDCl₃): δ 0.80 (3H, t, *J*=7.3 Hz, CH₂CH₃), 1.22–1.86 (4H, m, CH₂CH₂CH₃), 3.51 and 3.78 (6H, 2s, 2OCH₃), 3.81 (2H, dt, ²*J*=10.1 Hz, ³*J*=7.2 Hz, NCH₂), 5.52 (1H, s, N₂CHO), 6.38 (1H, s, Ar-CH), 6.81 and 6.92 (2H, 2s, NCH=CHN), 7.16 (2H, d, J=5.8 Hz, 2CH), 8.49 (2H, d, J=5.8 Hz, 2CH). ¹³C NMR (125.8 MHz, CDCl₃): δ 13.28 (CH₂CH₃), 19.49 and 32.82 (CH₂CH₂CH₃), 46.63 (NCH₂), 51.56 and 52.50 (2OCH₃), 75.60 (Ar-CH), 97.39 (N₂CHO), 120.36, 121.72, and 128.48 (3CH), 141.82 and 144.98 (2C), 150.20 (CH), 158.98 (C), 163.31 and 165.66 (2C=O).

Acknowledgements

This research was supported by the Research Council of University of Tehran as a research project (6102036/1/02).

References and notes

- 1. Laszlo, P. Organic Reactions: Simplicity and Logic; Wiley: New York, 1995.
- 2. Swinbourne, J. F.; Hunt, H. J.; Klinkert, G. Adv. Heterocycl. Chem. 1987, 23, 103.
- Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. *Nature* **2000**, *405*, 962.
- 4. Mullan, Z. Lancet 2000, 355, 2223.
- 5. Duncan, K. Tuberculosis 2003, 83, 201.
- Choi, K.-P.; Bair, T. B.; Bae, Y.-M.; Daniels, L. J. Bacteriol. 2001, 183, 7058.
- 7. Akira, K.; Tsuneo, K.; Kunio, H.; Fumiyoshi, I. *Chem. Pharm. Bull.* **1979**, *27*, 848.
- 8. Miyamoto, M.; Tomari, K.; Kimura, Y. Macromol. Chem. Phys. 1999, 200, 594.
- 9. Ferris, J. P.; Devadas, B. *Tetrahedron Lett.* **1986**, *27*, 323. Ferris, J. P.; Devadas, B. J. Org. Chem. **1987**, *52*, 2355.
- Luknitskii, F. I.; Taube, D. O.; Vovsi, B. A. Zh. Org. Khim. 1969, 5, 1844.
- 11. Shikhaliev, K. S.; Leshcheva, E. V.; Medvedeva, S. M. Chem. Heterocycl. Compd. 2002, 420, 852.
- Yavari, I.; Adib, M.; Jahani-Moghaddam, F.; Bijanzadeh, H. R. *Tetrahedron* 2002, 58, 6901.
- 13. Yavari, I.; Adib, M.; Sayahi, M. H. Tetrahedron Lett. 2002, 43, 2927.
- 14. Yavari, I.; Adib, M.; Hojabri, L. Tetrahedron 2002, 58, 6895.
- 15. Yavari, I.; Adib, M.; Sayahi, M. H. J. Chem. Soc., Perkin Trans. 1 2002, 13, 1517.
- Adib, M.; Mollahosseini, M.; Yavari, H.; Sayahi, M. H.; Bijanzadeh, H. R. Synlett 2004, 1086.
- 17. Adib, M.; Ghanbary, K.; Mostofi, M.; Bijanzadeh, H. R. *Tetrahedron* **2005**, *61*, 2645.
- Neuhaus, D.; Williamson, M. *The Nuclear Overhauser Effect* in Structural and Conformational Analysis; VCH: New York, 1989.